B-cell lymphoma 6 (BCL6) protein inhibits CD36 transcription by directly binding to the CD36 promoter region under physiological conditions and inhibits the progression of non-alcoholic fatty liver disease in mice in a CD36-dependent manner, including disordered lipid accumulation and glucose metabolism [45]. Here, BCL6 is linked to metabolic dysfunction-associated steatotic liver disease.